Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979796 | 0.91 | MEN1 (0.36) | MEN1KMT2ASMN1; SMN2POLBOPRM1 | |
| SCHEMBL16369921 | 0.81 | SMN1; SMN2 (0.33) | MEN1KMT2ASMN1; SMN2POLBOPRM1 | |
| SCHEMBL15105971 | 0.77 | SMN1; SMN2 (0.38) | MEN1KMT2ASMN1; SMN2POLBOPRM1 | |
| SCHEMBL16058884 | 0.74 | SMN1; SMN2 (0.39) | MEN1KMT2ASMN1; SMN2POLBOPRM1 | |
| SCHEMBL15105973 | 0.74 | BRD4 (0.40) | MEN1KMT2ASMN1; SMN2POLBOPRM1 | |
| SCHEMBL4788923 | 0.74 | ALDH1A1 (0.52) | MEN1KMT2ASMN1; SMN2POLBOPRM1 | |
| SCHEMBL15472954 | 0.73 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2POLBOPRM1 | |
| SCHEMBL15472979 | 0.72 | L3MBTL1 (0.37) | MEN1KMT2ASMN1; SMN2POLBOPRM1 | |
| SCHEMBL15114429 | 0.72 | SMN1; SMN2 (0.37) | MEN1KMT2ASMN1; SMN2POLBOPRM1 | |
| SCHEMBL15105602 | 0.70 | SMN1; SMN2 (0.36) | MEN1KMT2ASMN1; SMN2POLBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | MEN1 4834/4885KMT2A 4038/4885SMN1; SMN2 4705/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | MEN1 4834/4885KMT2A 4038/4885SMN1; SMN2 4705/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | MEN1 4813/4885KMT2A 4192/4885SMN1; SMN2 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.